Neumora Therapeutics, Common Stock Alpha and Beta Analysis
| NMRA Stock | 2.05 0.12 5.53% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neumora Therapeutics, Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neumora Therapeutics, over a specified time horizon. Remember, high Neumora Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neumora Therapeutics,'s market risk premium analysis include:
Beta 1.21 | Alpha (1.65) | Risk 11.51 | Sharpe Ratio (0.14) | Expected Return (1.56) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neumora |
Neumora Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neumora Therapeutics, market risk premium is the additional return an investor will receive from holding Neumora Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neumora Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neumora Therapeutics,'s performance over market.| α | -1.65 | β | 1.21 |
Neumora Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neumora Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Neumora Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Neumora Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Neumora Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neumora Therapeutics, shares will generate the highest return on investment. By understating and applying Neumora Therapeutics, stock market price indicators, traders can identify Neumora Therapeutics, position entry and exit signals to maximize returns.
Neumora Therapeutics, Return and Market Media
The median price of Neumora Therapeutics, for the period between Tue, Oct 22, 2024 and Mon, Jan 20, 2025 is 10.63 with a coefficient of variation of 39.12. The daily time series for the period is distributed with a sample standard deviation of 3.92, arithmetic mean of 10.02, and mean deviation of 2.69. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 14049 shares by Fust Matthew K of Neumora Therapeutics, at 17.0346 subject to Rule 16b-3 | 11/13/2024 |
2 | Neumora Therapeutics, Inc. This Small-Cap Stock Is Ready To Explode | 11/19/2024 |
3 | Acquisition by Arch Venture Partners Xii, Llc of 30773 shares of Neumora Therapeutics, at 10.8 subject to Rule 16b-3 | 11/29/2024 |
4 | This Is What Whales Are Betting On Neumora Therapeutics | 12/26/2024 |
5 | Disposition of 133097 shares by Paul Berns of Neumora Therapeutics, subject to Rule 16b-3 | 12/27/2024 |
6 | Neumora Therapeutics Shares Down 4.3 percent Whats Next | 12/31/2024 |
7 | Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA | 01/02/2025 |
8 | Equities Analysts Offer Predictions for NMRA FY2029 Earnings | 01/08/2025 |
About Neumora Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neumora or other stocks. Alpha measures the amount that position in Neumora Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Payables Turnover | 0.38 | 1.78 | 1.87 | Days Of Inventory On Hand | 6.77 | 7.78 | 7.39 |
Neumora Therapeutics, Upcoming Company Events
As portrayed in its financial statements, the presentation of Neumora Therapeutics,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neumora Therapeutics,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neumora Therapeutics,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neumora Therapeutics,. Please utilize our Beneish M Score to check the likelihood of Neumora Therapeutics,'s management manipulating its earnings.
| 7th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Neumora Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Neumora Therapeutics, Backtesting, Neumora Therapeutics, Valuation, Neumora Therapeutics, Correlation, Neumora Therapeutics, Hype Analysis, Neumora Therapeutics, Volatility, Neumora Therapeutics, History and analyze Neumora Therapeutics, Performance. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Neumora Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.